• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioCardia Inc. (Amendment)

    2/14/24 5:06:32 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCDA alert in real time by email
    SC 13G/A 1 d742671dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2

    (Amendment No. 1)*

     

     

    BioCardia, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    09060U507

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

     

    * 

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 09060U507    13G    Page 1 of 5 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Thomas A. Satterfield, Jr.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     265,000

       6.  

     SHARED VOTING POWER

     

     1,436,000

       7.  

     SOLE DISPOSITIVE POWER

     

     265,000

       8.  

     SHARED DISPOSITIVE POWER

     

     1,436,000

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,701,000

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     7.87%*

    12.  

     TYPE OF REPORTING PERSON

     

     IN

     

    *

    Based on 21,619,432 shares of common stock of the issuer outstanding as of October 31, 2023, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023.


    CUSIP No. 09060U507    13G    Page 2 of 5 Pages

     

    SCHEDULE 13G

    Item 1.

     

      (a)

    Name of Issuer:

    BioCardia, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    320 Soquel Way

    Sunnyvale, CA 94085

    Item 2.

     

      (a)

    Name of Person Filing:

    Thomas A. Satterfield, Jr.

     

      (b)

    Address of Principal Business Office or, if none, Residence:

    Thomas A. Satterfield, Jr.

    15 Colley Cove Drive

    Gulf Breeze, Florida 32561

     

      (c)

    Citizenship:

    Incorporated by reference from Item 4 of the Cover Pages.

     

      (d)

    Title of Class of Securities:

    Incorporated by reference from the Cover Pages.

     

      (e)

    CUSIP Number:

    Incorporated by reference from the Cover Pages.

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    Incorporated by reference from Item 9 of the Cover Pages.

     

      (b)

    Percent of class:

    Incorporated by reference from Item 11 of the Cover Pages.


    CUSIP No. 09060U507    13G    Page 3 of 5 Pages

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote

    Incorporated by reference from Item 5 of the Cover Pages.

     

      (ii)

    Shared power to vote or to direct the vote

    Incorporated by reference from Item 6 of the Cover Pages.

     

      (iii)

    Sole power to dispose or to direct the disposition of

    Incorporated by reference from Item 7 of the Cover Pages.

     

      (iv)

    Shared power to dispose or to direct the disposition of

    Incorporated by reference from Item 8 of the Cover Pages.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 300,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 700,000 shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; and 426,000 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield.

    Additionally, Mr. Satterfield has a limited power of attorney for voting and disposition purposes with respect to the following shares: Rebecca A. Satterfield (10,000 shares). Ms. Satterfield has the right to receive or the power to direct the receipt of the proceeds from the sale of her shares.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.


    CUSIP No. 09060U507    13G    Page 4 of 5 Pages

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 09060U507    13G    Page 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024

    Date

     

    /s/ Thomas A. Satterfield, Jr.

    Thomas A. Satterfield, Jr.
    Get the next $BCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCDA

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCDA
    SEC Filings

    See more
    • BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BioCardia, Inc. (0000925741) (Filer)

      5/6/25 8:00:09 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioCardia, Inc. (0000925741) (Filer)

      5/1/25 9:00:10 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by BioCardia Inc.

      S-3 - BioCardia, Inc. (0000925741) (Filer)

      4/30/25 5:13:07 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Krasno Richard M bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 417% to 16,268 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/28/25 6:46:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mcclung David bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 44% to 43,131 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:38:27 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Facteau Bill bought $24,999 worth of shares (13,123 units at $1.90) (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:37:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Krasno Richard M bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 417% to 16,268 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/28/25 6:46:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mcclung David bought $24,999 worth of shares (13,123 units at $1.90), increasing direct ownership by 44% to 43,131 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:38:27 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Facteau Bill bought $24,999 worth of shares (13,123 units at $1.90) (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      4/25/25 9:37:32 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Financials

    Live finance-specific insights

    See more

    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

      SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration. For those who have no

      3/31/25 1:39:56 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

      Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significanceStatistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell TherapyPatient improvements through two years suggest single dose of CardiAMP therapy offers durable benefits SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for

      3/31/25 8:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study

      CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, to serve as Site Principal Investigator and Co-National Principal Investigator SUNNYVALE, Calif., May 06, 2025 (GLOBE NEWSWIRE) --  BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that University of Wisconsin in Madison, Wisconsin is now enrolling patients with ischemic HFrEF in

      5/6/25 8:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure

      SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled in the Phase III randomized procedure placebo-controlled double-blind CardiAMP HF II clinical trial of the Company's lead autologous cell therapy program for the treatment of heart failure at BayCare Morton Plant Hospital in Clearwater, Florida. "We are excited to lead enrollment in the CardiAMP HF II trial and be able to offer this cell therapy study to our heart failure patients. This investigational therapy has been shown to enhance micro

      5/1/25 9:00:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioCardia Inc.

      SC 13G - BioCardia, Inc. (0000925741) (Subject)

      9/6/24 7:45:48 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      4/5/24 4:13:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      2/27/24 4:53:40 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BioCardia with a new price target

      HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00

      12/20/21 6:05:04 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia downgraded by Dawson James

      Dawson James downgraded BioCardia from Buy to Neutral

      4/16/21 7:22:02 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care